Key result
Bovine jugular vein conduits carry a ~6% infective endocarditis risk, exceeding homografts and ePTFE.
Why the study?
Homograft, bovine jugular vein, and ePTFE are commonly used valved conduits for RVOT reconstruction, but their relative performance remained unclear.
Do bovine jugular vein and ePTFE valved conduits have comparable mortality, replacement rates, and infective endocarditis incidence compared to homograft in patients undergoing right ventricular outflow tract reconstruction?
Population
Patients undergoing RVOT reconstruction across 28 retrospective cohort studies (n = 3966) and 113 case-series reports (n = 16 367)
Comparison
Homograft vs bovine jugular vein vs ePTFE valved conduits
Design
Systematic review and meta-analysis
Authors
Loading...
Supports heightened IE surveillance with bovine jugular vein conduits; leaves open optimal choice pending randomized trials.
Do bovine jugular vein and ePTFE valved conduits have comparable mortality, replacement rates, and infective endocarditis incidence compared to homograft in patients undergoing right ventricular outflow tract reconstruction?
Bovine jugular vein and ePTFE are viable alternatives to homograft for RVOT reconstruction with comparable mortality and replacement rates, though BJV carries a significantly higher risk of infective endocarditis.
Wang et al. (2026) studied this question. Bovine jugular vein conduits had a significantly higher incidence of infective endocarditis (6%) compared to homografts (2%) and ePTFE (1%), posing a risk that requires careful monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: